MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn-Schmiedeberg’s ...

Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American ... name for its lead molecule THIO, a telomere-targeting anticancer agent in clinical development as a first-in-class treatment ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing ...

(RTTNews) - MAIA Biotechnology Inc. (MAIA), on Wednesday ... nonproprietary name for its investigational anticancer agent, THIO. The approval is an important step in the regulatory process ...

CHICAGO, April 01, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

MAIA Biotechnology (MAIA) announced that the United States Adopted Names Council has approved “ateganosine” as the nonproprietary name for its ...

CHICAGO, March 20, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn ...

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders ...